Georgia Medicare Colorectal Cancer Screening 2026 Guide

By Brevy Care Team

Medicare covers colorectal cancer screening for eligible beneficiaries through a benefit established by Section 4104 of the Balanced Budget Act of 1997 (BBA, Public Law 105-33), codified at Section 1861(pp) of the Social Security Act (42 U.S.C. 1395x(pp)), and implemented at 42 CFR 410.37. The benefit became effective January 1, 1998 and has been expanded numerous times since to add new modalities (Cologuard FIT-DNA, FIT), to align with USPSTF guidance lowering the start age to 45, and to protect beneficiaries from unexpected cost-sharing when a polyp is removed during a screening colonoscopy.

For Georgia Medicare beneficiaries, the colorectal cancer screening benefit is one of the most impactful preventive services in the Medicare statute. Colorectal cancer is the third most common cancer in the United States and a leading cause of cancer death. Georgia faces elevated colorectal cancer mortality, particularly in rural Black Belt counties where access to gastroenterology services is limited and African American beneficiaries face documented disparities in incidence and mortality. The breadth of covered modalities — stool-based tests that can be completed at home, endoscopic procedures, and contrast studies — means nearly every eligible beneficiary has a workable screening pathway regardless of geography, mobility, or personal preference. This guide explains the statutory framework, eligibility, covered modalities, coding, cost-sharing structure, the critically important screen-to-diagnostic conversion protections, and the Georgia gastroenterology landscape so beneficiaries, families, and clinicians can navigate the benefit with confidence.

Key Takeaways

1. Statutory authority: Section 1861(pp) of the Social Security Act defines colorectal cancer screening as a covered Medicare service. The benefit was added by Section 4104 of the Balanced Budget Act of 1997 (Public Law 105-33), signed August 5, 1997, with coverage effective January 1, 1998.
2. Implementing regulation: 42 CFR 410.37 specifies the regulatory framework including covered modalities, frequency limits, risk categorization, and provider requirements.
3. Multiple covered modalities: Medicare covers stool-based tests (Fecal Occult Blood Test, Fecal Immunochemical Test, Cologuard FIT-DNA), endoscopic procedures (flexible sigmoidoscopy, colonoscopy), and contrast enema. Each modality has specific frequency and eligibility rules.
4. Age 45 eligibility: Following the 2021 USPSTF recommendation update lowering the screening start age from 50 to 45, CMS aligned coverage effective January 1, 2023 through final rulemaking.
5. Risk stratification: Average-risk beneficiaries qualify for less frequent endoscopic screening (every 10 years for colonoscopy, every 4 years for sigmoidoscopy). High-risk beneficiaries qualify for more frequent screening (every 2 years for colonoscopy).
6. High-risk category definitions: Personal history of adenomatous polyps, personal history of colorectal cancer, inflammatory bowel disease (Crohn disease or ulcerative colitis), family history of colorectal cancer or polyps, Lynch syndrome (hereditary nonpolyposis colorectal cancer), and familial adenomatous polyposis.
7. HCPCS coding: G0104 (flexible sigmoidoscopy), G0105 (colonoscopy high risk), G0106 (barium enema high risk), G0120 (barium enema average risk), G0121 (colonoscopy average risk), G0328 (FIT), 81528 (Cologuard FIT-DNA), 82270 (FOBT).
8. ACA cost-sharing waiver: Section 4104 of the Affordable Care Act eliminated Part B deductible and coinsurance for USPSTF Grade A or B aligned screening colorectal cancer modalities effective January 1, 2011.
9. Screen-to-diagnostic conversion protection: Section 122 of the Consolidated Appropriations Act, 2021 protects beneficiaries from cost-sharing when a polyp is found and removed during a screening colonoscopy. The phased cost-sharing reduction began January 1, 2022 and completes by 2030.
10. Georgia landscape: Major Georgia gastroenterology programs include Emory Digestive Health, Wellstar Gastroenterology, Piedmont GI, Northside Hospital GI, and Augusta University GI. Rural access remains a challenge in southwest and southeast Georgia, making stool-based testing modalities a critical access tool.

Part 1: The Statutory and Regulatory Framework

Section 1861(pp) of the Social Security Act

Section 1861(pp) of the Social Security Act (42 U.S.C. 1395x(pp)) defines "colorectal cancer screening tests" for Medicare coverage purposes. The statute lists the categories of services Medicare may cover: screening fecal-occult blood tests, screening flexible sigmoidoscopies, screening colonoscopies (including screening for individuals at high risk for colorectal cancer), and screening barium enemas (when used as an alternative to either a screening flexible sigmoidoscopy or a screening colonoscopy). The statute also authorizes the Secretary of Health and Human Services to add other tests or procedures determined to be appropriate for the purpose of screening for colorectal cancer through the National Coverage Determination process.

This authorization language is what allowed CMS to add coverage for the Fecal Immunochemical Test (FIT) and later the Cologuard FIT-DNA multitarget stool DNA test as scientific evidence supported their effectiveness. The flexibility of Section 1861(pp) is part of why colorectal cancer screening coverage has evolved more dynamically than many other preventive benefits in the Medicare statute.

Balanced Budget Act of 1997 Section 4104 Origin

The colorectal cancer screening benefit was established by Section 4104 of the Balanced Budget Act of 1997 (BBA, Public Law 105-33). President Clinton signed the BBA into law on August 5, 1997. The colorectal cancer screening benefit became effective for services furnished on or after January 1, 1998. At that time, the covered modalities were the fecal occult blood test, flexible sigmoidoscopy, screening colonoscopy for high-risk beneficiaries, and barium enema as an alternative to endoscopy.

Significant expansions since 1998 include:

• 2001: Screening colonoscopy extended to average-risk beneficiaries (every 10 years), not only high-risk individuals.
• 2004: Coverage updated to clarify high-risk category definitions and screening frequency limits through CMS rulemaking.
• 2014: Fecal Immunochemical Test (FIT) added as a covered annual stool-based screening modality.
• 2014: Cologuard FIT-DNA multitarget stool DNA test added as a covered every-three-years stool-based screening modality.
• January 1, 2022: Consolidated Appropriations Act 2021 Section 122 screen-to-diagnostic conversion cost-sharing protection took effect.
• January 1, 2023: CMS aligned coverage start age with the 2021 USPSTF recommendation lowering screening start age from 50 to 45.

42 CFR 410.37 Implementing Regulations

The implementing regulations for colorectal cancer screening are codified at 42 CFR 410.37. The regulations specify:

• The covered modalities and their respective HCPCS codes.
• The screening frequency limits for each modality.
• The risk stratification definitions distinguishing average-risk from high-risk beneficiaries.
• The provider requirements for performing each modality.
• The clinical setting requirements for endoscopic procedures.
• The coordination with Medicare diagnostic services when a screening procedure identifies abnormalities requiring intervention.

Related Statutory and Regulatory Authority

Section 1861(pp) does not exist in isolation. Several other Medicare preventive services statutes interact with the colorectal cancer screening benefit:

• Section 1861(ww) SSA — Initial Preventive Physical Examination (IPPE, the Welcome to Medicare visit). Often the first point of contact when colorectal cancer screening is ordered.
• Section 1861(hhh) SSA — Annual Wellness Visit (AWV). Includes a personalized prevention plan that documents colorectal cancer screening status and recommendations.
• Section 1861(ddd) SSA — General preventive services framework. Establishes how preventive services interact with USPSTF recommendations.
• ACA Section 4104 (Public Law 111-148) — The Affordable Care Act preventive services cost-sharing waiver effective January 1, 2011. Eliminated Part B deductible and coinsurance for USPSTF Grade A or B aligned preventive services.
• CAA 2021 Section 122 (Public Law 116-260) — The Consolidated Appropriations Act, 2021 screen-to-diagnostic conversion protection.

Part 2: Eligible Beneficiaries and Risk Stratification

Age Eligibility

Medicare beneficiaries become eligible for colorectal cancer screening at age 45 for average-risk individuals, following the 2021 USPSTF recommendation update that lowered the screening start age from 50 to 45 in response to rising colorectal cancer incidence in younger adults. CMS aligned Medicare coverage with this updated USPSTF recommendation through its 2023 final rule.

High-risk beneficiaries may be eligible for screening at younger ages depending on the specific risk factor. For example, beneficiaries with a strong family history may be advised to begin screening 10 years before the earliest age of diagnosis in a first-degree relative. Inflammatory bowel disease patients typically begin surveillance colonoscopy 8 to 10 years after disease onset regardless of age.

Note that most Medicare beneficiaries enroll at age 65, so the practical impact of the age-45 expansion for Medicare specifically affects beneficiaries who enroll early through disability eligibility or End-Stage Renal Disease eligibility.

Average-Risk Versus High-Risk Stratification

Medicare uses two risk categories for colorectal cancer screening:

Average risk applies to beneficiaries without any qualifying high-risk factor. Average-risk screening frequency limits are:

• Annual FOBT or FIT.
• Every 3 years Cologuard FIT-DNA.
• Every 4 years flexible sigmoidoscopy (or 120 months following a screening colonoscopy).
• Every 10 years screening colonoscopy (or 48 months following a screening flexible sigmoidoscopy).
• Barium enema as alternative to sigmoidoscopy or colonoscopy.

High risk applies to beneficiaries with at least one qualifying high-risk factor. High-risk screening frequency limits are:

• Every 2 years screening colonoscopy.
• Stool-based tests at average-risk frequencies.

High-Risk Category Definitions

The implementing regulations and CMS sub-regulatory guidance define the following high-risk categories for colorectal cancer screening:

1. Personal history of adenomatous polyps — Prior diagnosis of an adenomatous polyp regardless of size or histology elevates colorectal cancer risk and qualifies beneficiaries for more frequent screening.

2. Personal history of colorectal cancer — Beneficiaries with a prior colorectal cancer diagnosis (now in surveillance) qualify for more frequent screening colonoscopy.

3. Inflammatory bowel disease — Crohn disease or ulcerative colitis affecting the colon elevates colorectal cancer risk substantially. Surveillance colonoscopy typically begins 8 to 10 years after disease onset with frequency determined by extent of disease and severity of inflammation.

4. Family history of colorectal cancer or polyps — A first-degree relative (parent, sibling, or child) diagnosed with colorectal cancer or adenomatous polyps before age 60, or two first-degree relatives at any age, qualifies a beneficiary as high-risk.

5. Lynch syndrome (hereditary nonpolyposis colorectal cancer, HNPCC) — A hereditary cancer syndrome caused by germline mutations in DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM) that confer dramatically elevated lifetime colorectal cancer risk along with elevated risk of endometrial, ovarian, and other cancers.

6. Familial adenomatous polyposis (FAP) — A hereditary syndrome caused by APC gene germline mutations producing hundreds to thousands of colonic adenomas and near-certain colorectal cancer without prophylactic colectomy.

7. Other documented high-risk factors — CMS guidance allows clinical documentation of other high-risk factors at provider discretion when appropriately documented.

Part 3: Covered Screening Modalities

Fecal Occult Blood Test (FOBT)

The Fecal Occult Blood Test detects microscopic blood in stool that may indicate bleeding from a colorectal cancer or large adenomatous polyp. Medicare covers FOBT annually for beneficiaries age 45 and older. The HCPCS code is 82270. The test requires the beneficiary to collect stool samples at home over several bowel movements and return them to the laboratory for analysis. FOBT is the oldest covered stool-based screening modality and remains a low-cost option, though it has been substantially superseded by FIT in clinical practice due to superior performance characteristics.

Fecal Immunochemical Test (FIT)

The Fecal Immunochemical Test uses antibodies specific to human hemoglobin to detect blood in stool. It is more sensitive and specific than guaiac-based FOBT and does not require dietary restrictions or medication holds before testing. Medicare covers FIT annually for beneficiaries age 45 and older. The HCPCS code is G0328. FIT has become the dominant stool-based screening modality in clinical practice and is particularly valuable for beneficiaries who lack access to or decline endoscopic screening.

Cologuard FIT-DNA Multitarget Stool DNA Test

Cologuard (Exact Sciences) is a multitarget stool DNA test that combines the fecal immunochemical test for hemoglobin with assays for DNA biomarkers associated with colorectal cancer (KRAS mutations, methylated DNA markers). Medicare covers Cologuard every three years for average-risk asymptomatic beneficiaries age 45 and older. The HCPCS code is 81528. Cologuard offers higher sensitivity than FIT alone but at higher cost and with higher false-positive rates, particularly in older beneficiaries. It is particularly useful for beneficiaries with limited mobility, those declining endoscopy, and those in geographically isolated settings where colonoscopy access is constrained.

Flexible Sigmoidoscopy

Flexible sigmoidoscopy is an endoscopic examination of the rectum, sigmoid colon, and descending colon (typically up to the splenic flexure). It does not examine the proximal colon (ascending colon and cecum). Medicare covers screening flexible sigmoidoscopy every 4 years for average-risk beneficiaries (or 120 months after a screening colonoscopy). The HCPCS code is G0104. Sigmoidoscopy can be performed without full bowel preparation and without sedation, making it more accessible in some settings, but its coverage of only the distal colon means it cannot detect proximal colonic lesions and has largely been replaced by colonoscopy in clinical practice.

Screening Colonoscopy

Screening colonoscopy is an endoscopic examination of the entire colon (rectum, sigmoid, descending colon, transverse colon, ascending colon, and cecum). It is the gold standard for colorectal cancer screening because it examines the entire colon and allows for biopsy and removal of polyps during the procedure. Medicare covers screening colonoscopy:

• Average risk (HCPCS G0121): Every 10 years for asymptomatic beneficiaries age 45 and older. Coverage requires that 48 months have passed since the most recent screening flexible sigmoidoscopy.
• High risk (HCPCS G0105): Every 2 years for beneficiaries with at least one qualifying high-risk factor.

Screening colonoscopy requires full bowel preparation (typically polyethylene glycol solution the day before the procedure) and is performed under sedation or anesthesia in an outpatient endoscopy facility, ambulatory surgery center, or hospital outpatient department.

Barium Enema

Barium enema involves rectal infusion of barium contrast followed by radiographic imaging to outline the colonic lumen. Medicare covers screening barium enema as an alternative to either screening flexible sigmoidoscopy or screening colonoscopy when the beneficiary cannot undergo endoscopy. The HCPCS codes are G0106 (barium enema alternative to sigmoidoscopy) and G0120 (barium enema alternative to colonoscopy). Barium enema is rarely used in current practice due to inferior sensitivity compared to colonoscopy and has been largely replaced by colonoscopy and stool-based testing.

Frequency Schedule Summary

Part 4: Cost-Sharing Structure

ACA Section 4104 Cost-Sharing Waiver

Section 4104 of the Affordable Care Act (Public Law 111-148) eliminated Part B deductible and coinsurance for USPSTF Grade A or B aligned preventive services effective January 1, 2011. The USPSTF has graded colorectal cancer screening Grade A for adults age 50 to 75 and Grade B for adults age 45 to 49 (per the 2021 update). Both Grade A and Grade B align with the ACA cost-sharing waiver.

Therefore, for USPSTF-aligned screening colorectal cancer modalities (FOBT, FIT, Cologuard FIT-DNA, flexible sigmoidoscopy, average-risk colonoscopy, high-risk colonoscopy when supported by qualifying clinical history), Medicare beneficiaries pay $0 for the screening service itself when furnished by a provider that accepts Medicare assignment.

Screen-to-Diagnostic Conversion: The Historic Problem

Before 2022, a major beneficiary cost-sharing problem existed at the screening colonoscopy: if the gastroenterologist identified and removed a polyp during what was scheduled as a screening colonoscopy, the procedure was reclassified from screening to diagnostic, and the beneficiary faced cost-sharing on the procedure. Beneficiaries who entered the procedure expecting zero cost-sharing under the ACA waiver received bills for hundreds of dollars in coinsurance.

This "screening-to-diagnostic conversion" cost-sharing was widely criticized as a financial barrier to screening colonoscopy uptake because beneficiaries could not know in advance whether their procedure would convert. The American Cancer Society, gastroenterology professional societies, and patient advocacy organizations advocated for legislative protection.

Consolidated Appropriations Act 2021 Section 122 Protection

Section 122 of the Consolidated Appropriations Act, 2021 (Public Law 116-260), signed by President Trump on December 27, 2020, addresses screen-to-diagnostic conversion cost-sharing through a phased reduction:

• January 1, 2022 through December 31, 2026: Coinsurance reduced to 15% on the conversion (down from 20%).
• January 1, 2027 through December 31, 2029: Coinsurance reduced to 10%.
• January 1, 2030 and thereafter: Coinsurance reduced to 0% (full elimination).

The Part B deductible is not waived under this protection because the protection addresses only the coinsurance portion. The screening service itself remains $0 because the ACA Section 4104 waiver continues to apply.

This phased approach reflects budgetary considerations and represents a meaningful but incomplete protection. Beneficiaries undergoing screening colonoscopy in 2026 still face some coinsurance if a polyp is removed during the procedure, though the burden is substantially reduced compared to the pre-2022 framework.

Cost-Sharing Summary Table

Part 5: Coordination With Other Medicare Preventive Services

Coordination With the Annual Wellness Visit

The Annual Wellness Visit (AWV), authorized by Section 1861(hhh) of the Social Security Act and added by Section 4103 of the Affordable Care Act, includes a personalized prevention plan that documents preventive services status and recommendations. Colorectal cancer screening is a routine AWV component:

• Documentation of most recent screening date and modality.
• Risk assessment for high-risk categorization.
• Discussion of preferred screening modality.
• Referral for screening when due.
• Coordination of timing with other preventive services.

Coordination With the Initial Preventive Physical Examination

The Initial Preventive Physical Examination (IPPE, also known as the Welcome to Medicare visit), authorized by Section 1861(ww) of the Social Security Act, is the one-time preventive visit available within the first 12 months of Part B enrollment. The IPPE includes assessment of preventive services needs and orders for appropriate screening. Beneficiaries who have never been screened for colorectal cancer often receive their first Medicare-covered screening order during the IPPE.

Coordination With Cardiovascular Disease Screening and Diabetes Screening

While colorectal cancer screening is distinct from cardiovascular disease screening (Section 1861(xx)) and diabetes screening (Section 1861(yy)), all three benefits share the ACA Section 4104 cost-sharing waiver and are routinely coordinated through the AWV. Beneficiaries often receive multiple preventive screenings in proximity, and the AWV serves as the coordinating visit.

Part 6: Provider Requirements

Provider Categories

Colorectal cancer screening services are performed by:

• Gastroenterologists — Internal medicine physicians with subspecialty training in gastroenterology and hepatology. Perform colonoscopy, flexible sigmoidoscopy.
• Colorectal surgeons — Surgeons specializing in colorectal disease. Also perform colonoscopy and flexible sigmoidoscopy.
• General surgeons — May perform colonoscopy and flexible sigmoidoscopy in some settings, particularly rural facilities.
• Primary care physicians — Order FOBT, FIT, and Cologuard. Some primary care physicians also perform flexible sigmoidoscopy.
• Radiologists — Perform barium enema studies.

Facility Requirements

Endoscopic procedures (colonoscopy, flexible sigmoidoscopy) are typically performed in:

• Hospital outpatient endoscopy units.
• Ambulatory surgery centers (ASCs).
• Office-based endoscopy suites.

CMS pays differently across these settings, and beneficiaries should be aware that out-of-pocket costs may vary depending on facility type even when the ACA Section 4104 waiver applies to the screening service itself.

Georgia Provider Licensure

In Georgia, gastroenterologists and colorectal surgeons are licensed by the Georgia Composite Medical Board. Endoscopy nurses are licensed by the Georgia Board of Nursing. Anesthesiologists (when sedation is administered by anesthesia services rather than the gastroenterologist) are similarly licensed by the Georgia Composite Medical Board.

Part 7: The Major Georgia Gastroenterology Landscape

Atlanta Metropolitan Area

The Atlanta metropolitan area has substantial gastroenterology capacity:

• Emory Digestive Health — Academic gastroenterology center at Emory University. Offers comprehensive endoscopy services and serves as a referral center for complex cases. 404-778-3184.
• Wellstar Gastroenterology — Network-wide gastroenterology coverage across the north and west Atlanta metropolitan area and surrounding regions.
• Piedmont GI — Piedmont Healthcare gastroenterology with multiple endoscopy locations across the Atlanta metropolitan area and beyond.
• Northside Hospital GI — Strong gastroenterology presence particularly in the north Atlanta area.
• Atlanta Gastroenterology Associates — Large independent gastroenterology practice with multiple endoscopy centers throughout metropolitan Atlanta.

Augusta and East Georgia

Augusta University Health serves east Georgia with the Digestive Health Center providing gastroenterology and endoscopy services. The CSRA (Central Savannah River Area) is served by University Hospital, Doctors Hospital, and various independent gastroenterology practices.

Macon and Central Georgia

Atrium Health Navicent (Macon) and Coliseum Medical Centers provide gastroenterology services for central Georgia, including Bibb County and surrounding rural counties. Houston Healthcare in Warner Robins serves Houston County.

Savannah and Coastal Georgia

Memorial Health (Savannah) and St. Joseph's Candler Health System serve coastal Georgia with comprehensive gastroenterology and endoscopy capacity.

Albany and Southwest Georgia

Phoebe Putney Memorial Hospital (Albany) is the primary gastroenterology resource for southwest Georgia, serving a large rural catchment including Dougherty, Lee, Worth, Mitchell, Baker, Calhoun, and surrounding counties.

Athens and Northeast Georgia

Piedmont Athens Regional and St. Mary's Health Care System provide gastroenterology services for the Athens area and northeast Georgia, including the broader Clarke, Oconee, Madison, and Jackson County region.

Rural Georgia Access

Many rural Georgia counties lack local gastroenterology providers. Beneficiaries in counties without local endoscopy facilities typically travel to regional medical centers (Albany, Macon, Augusta, Savannah, Athens, Atlanta) for screening colonoscopy. This geographic constraint is one of the most important reasons stool-based testing modalities (FIT, Cologuard) are critical access tools for rural Georgia beneficiaries. Stool-based tests can be ordered by primary care providers, mailed to the beneficiary, completed at home, and returned by mail for laboratory analysis, eliminating the geographic and logistical barriers that constrain endoscopic screening uptake.

Part 8: Colorectal Cancer Disease Burden in Georgia

Incidence and Mortality

Georgia faces colorectal cancer incidence and mortality rates that exceed the national average. The Georgia Comprehensive Cancer Registry tracks state-level data and consistently documents elevated colorectal cancer burden particularly in rural counties of south and southwest Georgia and in African American populations across the state.

Black Belt Mortality

The Black Belt region of south and southwest Georgia includes counties with historically high African American populations and persistent socioeconomic disparities. These counties consistently rank highest in Georgia colorectal cancer mortality. Contributing factors include limited gastroenterology access, lower screening uptake, later-stage diagnosis at presentation, and historical health system disparities.

African American Disparities

African Americans face higher colorectal cancer incidence and mortality than non-Hispanic whites nationally and in Georgia specifically. The disparity reflects multiple factors:

• Earlier age at diagnosis suggesting biological and possibly environmental risk factor differences.
• More distal colonic disease distribution (proximal colon disease historically underdetected by sigmoidoscopy).
• Lower screening uptake driven by access, insurance, and trust factors.
• Later-stage diagnosis at presentation.

The 2021 USPSTF recommendation lowering screening start age to 45 was partly motivated by rising young-adult colorectal cancer incidence and the documented African American disparities. The Medicare alignment with this recommendation effective January 1, 2023 supports screening at age 45 for the small but growing population of beneficiaries enrolled in Medicare before age 65 through disability eligibility.

Part 9: Worked Examples

Worked Example 1: Atlanta Average-Risk Age 65 Screening Colonoscopy

Beneficiary: 65-year-old in DeKalb County, no family history, no symptoms, no prior screening.

The beneficiary has an AWV with her primary care physician at Emory. The AWV documents that she has never had colorectal cancer screening. Her physician orders a screening colonoscopy with HCPCS G0121 (colonoscopy average risk). She schedules the procedure at Emory Endoscopy Center.

Procedure proceeds with full bowel preparation and sedation. No polyps are identified. Pathology is unnecessary. The procedure is billed as G0121, the ACA Section 4104 cost-sharing waiver applies, and the beneficiary pays $0. She is advised she does not need to repeat screening colonoscopy for 10 years (until age 75).

Worked Example 2: Rural Southwest Georgia FIT Testing Access

Beneficiary: 68-year-old in Worth County (population approximately 21,000), no family history, no prior screening.

The beneficiary's nearest gastroenterologist is at Phoebe Putney in Albany, 30 miles away. She has limited transportation and prefers to avoid the trip and the bowel preparation. Her primary care physician at the Worth County FQHC discusses screening modalities and she elects annual FIT testing.

The physician orders FIT (HCPCS G0328). The laboratory mails a kit to her home. She collects the sample and returns it by mail. The result is negative. The ACA Section 4104 cost-sharing waiver applies and the beneficiary pays $0. She is scheduled for annual FIT in subsequent years through her primary care record.

Worked Example 3: Augusta Family History High-Risk Colonoscopy

Beneficiary: 60-year-old in Richmond County, mother diagnosed with colon cancer at age 55.

Family history of colorectal cancer in a first-degree relative diagnosed before age 60 qualifies the beneficiary as high-risk. Her primary care physician refers her to Augusta University Digestive Health Center for a high-risk screening colonoscopy with HCPCS G0105.

Procedure proceeds normally. Two small (less than 5 mm) hyperplastic polyps are identified in the sigmoid colon. Hyperplastic polyps are not premalignant and do not affect future screening intervals. The procedure is billed as G0105. Because hyperplastic polyps (not adenomatous polyps) were identified, the procedure is treated as a clean screening colonoscopy and the ACA Section 4104 cost-sharing waiver applies fully — the beneficiary pays $0.

She is advised to repeat high-risk screening colonoscopy in 5 years given her family history (the high-risk frequency limit of every 2 years applies but clinical judgment supports a 5-year interval given negative findings in this procedure).

Worked Example 4: Polyp Removed During Screening Colonoscopy — CAA 2021 Section 122

Beneficiary: 70-year-old in Cobb County, average-risk, screening colonoscopy at Wellstar.

Procedure begins as average-risk screening colonoscopy with HCPCS G0121. A 1.2 cm tubular adenoma is identified in the ascending colon and removed by polypectomy. The procedure converts to a screen-to-diagnostic procedure.

Under the pre-2022 framework, the beneficiary would have paid 20% coinsurance on the procedure (approximately $200 to $400 depending on facility billing). Under the CAA 2021 Section 122 phased reduction effective for procedures in 2026, the beneficiary's coinsurance is reduced to 15% — approximately $150 to $300 in this scenario.

The Part B deductible is not waived under Section 122, so if the beneficiary has not yet met the annual Part B deductible ($240 in 2024, adjusted annually), that deductible would apply first before coinsurance.

Going forward, the beneficiary's coinsurance under Section 122 will reduce further: 10% from 2027 through 2029 and 0% from 2030 onward.

Given the tubular adenoma finding, the beneficiary is advised to repeat colonoscopy in 3 to 5 years (depending on adenoma characteristics and number) as surveillance, which would be billed differently than a screening colonoscopy.

Worked Example 5: Cologuard FIT-DNA Testing for Mobility-Limited Beneficiary

Beneficiary: 72-year-old in Macon, ambulatory dysfunction limiting her ability to undergo colonoscopy preparation and procedure.

The beneficiary's primary care physician at Atrium Health Navicent discusses screening modalities. Given her mobility limitations and reluctance to undergo bowel preparation, she elects Cologuard FIT-DNA testing.

The physician orders Cologuard (HCPCS 81528). Exact Sciences mails a kit to her home. She collects the stool sample with assistance and returns it by prepaid shipping. The result is negative. The ACA Section 4104 cost-sharing waiver applies and the beneficiary pays $0. She is scheduled to repeat Cologuard in 3 years.

Worked Example 6: Inflammatory Bowel Disease Surveillance Colonoscopy

Beneficiary: 66-year-old in Fulton County, ulcerative pancolitis diagnosed at age 35.

The beneficiary has a 31-year history of ulcerative colitis affecting the entire colon (pancolitis). She is high-risk for colorectal cancer due to long-standing inflammatory bowel disease. Her gastroenterologist at Emory Digestive Health orders surveillance colonoscopy with HCPCS G0105.

Procedure proceeds with multiple biopsies throughout the colon for dysplasia surveillance per inflammatory bowel disease surveillance protocols. No polyps are identified, but the biopsies are sent for histologic review. The procedure is billed as G0105 with the ACA Section 4104 cost-sharing waiver applying — the beneficiary pays $0 for the procedure. The biopsies are processed and reviewed; histology shows chronic active colitis without dysplasia.

She is advised to repeat surveillance colonoscopy in 1 to 2 years given the surveillance context.

Part 10: Best Practices

Best Practice 1: Document Risk Factors Carefully

Accurate documentation of high-risk factors determines whether the beneficiary qualifies for more frequent endoscopic screening. Family history, personal history of polyps or colorectal cancer, inflammatory bowel disease history, and hereditary syndromes should be carefully documented in the medical record at the AWV and other primary care visits.

Best Practice 2: Use the AWV to Coordinate Screening

The Annual Wellness Visit is the natural coordinating visit for colorectal cancer screening alongside other preventive services. Documenting screening status, ordering tests, and tracking follow-up at the AWV improves screening completion rates.

Best Practice 3: Discuss Modality Choice With Beneficiary

Multiple covered modalities give beneficiaries genuine choice. Discussing patient preferences (avoidance of bowel preparation, geographic constraints, modality sensitivity tradeoffs) supports informed shared decision-making and improves uptake.

Best Practice 4: Set Reminders for Stool-Based Testing

Annual FOBT, annual FIT, and every-three-years Cologuard require ongoing reminders in the medical record. EHR-based reminders and patient outreach materially improve repeated screening completion.

Best Practice 5: Educate Beneficiaries on Screen-to-Diagnostic Conversion

The CAA 2021 Section 122 phased reduction is widely under-recognized. Many beneficiaries still believe screening colonoscopy carries full 20% coinsurance if a polyp is removed. Pre-procedure education improves uptake and prevents misunderstanding when bills arrive.

Best Practice 6: Coordinate With Specialty Care

Beneficiaries with prior colorectal cancer, inflammatory bowel disease, or hereditary syndromes need coordinated surveillance with gastroenterology specialty care. Primary care should not independently order surveillance colonoscopy for these beneficiaries without specialty input.

Best Practice 7: Address Cologuard False-Positive Counseling

Cologuard has higher false-positive rates than FIT, particularly in older beneficiaries. Beneficiaries with positive Cologuard results need timely diagnostic colonoscopy. Pre-test counseling helps set expectations.

Best Practice 8: Confirm Provider and Facility Acceptance of Medicare Assignment

ACA Section 4104 cost-sharing waiver applies only when providers accept Medicare assignment. Some private endoscopy facilities or providers may charge above assignment amounts, exposing beneficiaries to additional costs.

Best Practice 9: Verify Bowel Preparation Tolerance

Bowel preparation is the most common reason beneficiaries decline or fail screening colonoscopy. Discussing preparation tolerance, alternative preparation regimens (split-dose preparation, lower-volume alternatives), and accommodations for medical conditions improves preparation adequacy and procedure success.

Best Practice 10: Coordinate Anesthesia Provider Billing

When anesthesia services are provided separately by an anesthesiologist (rather than the gastroenterologist administering sedation), the anesthesia services may be billed separately and may not be fully waived under the ACA Section 4104 framework. Beneficiaries should be informed of this potential cost.

Best Practice 11: Document AWV Screening Discussion

The AWV personalized prevention plan should document the colorectal cancer screening discussion, modality choice, and any deferrals or beneficiary refusals along with reasons. This documentation supports quality measures and ensures continuity if the beneficiary's care transitions.

Best Practice 12: Track Surveillance Intervals After Polyp Removal

Beneficiaries with adenomatous polyps removed during a screening colonoscopy are placed on surveillance intervals rather than continued screening intervals. Tracking these intervals is essential for appropriate follow-up and prevents undertesting or overtesting.

Best Practice 13: Engage With Hereditary Cancer Risk Assessment

Beneficiaries with multiple first-degree relatives with colorectal cancer, early-onset colorectal cancer in relatives, or family histories suggestive of Lynch syndrome or familial adenomatous polyposis should be referred for hereditary cancer risk assessment with potential genetic counseling.

Best Practice 14: Address Rural Access With Stool-Based Testing

Rural Georgia counties lack convenient endoscopy access. Stool-based testing (FIT, Cologuard) is the most important access tool for these beneficiaries. Primary care practices should normalize stool-based testing as a high-quality screening pathway rather than a fallback.

Part 11: Common Issues

Common Issue 1: Confusion About Age 45 Versus Age 50 Eligibility

The Medicare age 45 alignment is recent (effective January 1, 2023). Some clinicians still operate under age 50 mental models, particularly for Medicare populations where most beneficiaries are over age 65 anyway. Updating clinical practice to age 45 is important for the small but growing population of pre-65 Medicare beneficiaries.

Common Issue 2: Misunderstanding Screen-to-Diagnostic Conversion

Many beneficiaries believe screening colonoscopy is fully covered regardless of findings. The CAA 2021 Section 122 phased reduction substantially improved the framework but did not eliminate cost-sharing until 2030. Pre-procedure education is essential.

Common Issue 3: Incorrect HCPCS Code Selection

Using G0121 (average-risk colonoscopy) when the beneficiary qualifies as high-risk under G0105 produces incorrect billing and may result in incorrect frequency interval tracking. Careful risk documentation supports correct coding.

Common Issue 4: Cologuard Used in High-Risk Beneficiaries

Cologuard is approved and Medicare-covered only for average-risk asymptomatic beneficiaries. Beneficiaries with high-risk factors should undergo colonoscopy rather than Cologuard. Using Cologuard in high-risk beneficiaries is clinically inappropriate.

Common Issue 5: Forgetting Frequency Coordination Across Modalities

Medicare coordinates frequency across modalities (for example, screening colonoscopy cannot be billed within 48 months of a screening flexible sigmoidoscopy). Tracking prior screening modality and date is essential for correct billing and authorization.

Common Issue 6: Anesthesia Services Billed Separately

When anesthesia is provided by a separate anesthesiologist, the anesthesia service may not be fully covered under the ACA Section 4104 waiver. Beneficiaries may face anesthesia coinsurance even when the screening procedure itself is fully waived.

Common Issue 7: Rural Beneficiaries Defaulting to No Screening

Rural beneficiaries without convenient endoscopy access sometimes default to no screening rather than using stool-based testing. Primary care normalization of stool-based testing as a high-quality screening pathway addresses this gap.

Common Issue 8: Failure to Document Family History Carefully

Family history-based high-risk eligibility requires specific documentation of relationship (first-degree), age at relative's diagnosis, and type of relative's diagnosis (cancer versus polyps). Incomplete documentation prevents correct high-risk classification.

Common Issue 9: Beneficiary Anxiety About Bowel Preparation

Bowel preparation is the most common barrier to screening colonoscopy completion. Beneficiaries who anticipate intolerable preparation often defer or refuse colonoscopy. Discussing preparation regimens, accommodations, and alternatives addresses this.

Common Issue 10: Cologuard Annual Versus 3-Year Confusion

Cologuard is covered every 3 years, not annually. Some beneficiaries and providers confuse Cologuard frequency with FIT frequency (annual). Correct interval tracking prevents undertesting or overtesting.

Common Issue 11: Surveillance Versus Screening Distinction

Beneficiaries with prior adenomatous polyps or colorectal cancer are on surveillance protocols, not screening protocols. Surveillance colonoscopy is billed differently from screening colonoscopy and is not subject to the ACA Section 4104 waiver.

Common Issue 12: Provider Network Constraints in Medicare Advantage

Medicare Advantage plans may have provider network constraints affecting which gastroenterologists or endoscopy facilities beneficiaries can use. Out-of-network use can result in higher cost-sharing even for ACA-aligned screening.

Common Issue 13: Documentation Gaps After Outside Procedures

When beneficiaries undergo colonoscopy at outside facilities (for example, travel to family in another state, or use of a specialty facility), the procedure and findings may not be communicated back to the primary care record. This produces frequency interval gaps and potential duplicate testing.

Common Issue 14: Failure to Address Hereditary Risk

Beneficiaries with strong family histories suggestive of Lynch syndrome or familial adenomatous polyposis are sometimes managed with standard high-risk screening rather than appropriate hereditary cancer evaluation. Genetic counseling referral and germline testing may be indicated.

Frequently Asked Questions

1. What law established Medicare coverage for colorectal cancer screening?

Section 4104 of the Balanced Budget Act of 1997 (Public Law 105-33), signed August 5, 1997, established the colorectal cancer screening benefit codified at Section 1861(pp) of the Social Security Act with coverage effective January 1, 1998.

2. What is the implementing regulation?

42 CFR 410.37 specifies the regulatory framework including covered modalities, frequency limits, risk categorization, and provider requirements.

3. At what age can I begin colorectal cancer screening under Medicare?

Average-risk beneficiaries can begin screening at age 45 per the 2021 USPSTF recommendation update, with Medicare coverage aligned effective January 1, 2023.

4. What modalities does Medicare cover for colorectal cancer screening?

Medicare covers Fecal Occult Blood Test (FOBT), Fecal Immunochemical Test (FIT), Cologuard FIT-DNA multitarget stool DNA test, flexible sigmoidoscopy, screening colonoscopy (average-risk and high-risk), and barium enema as alternative to endoscopy.

5. How often can I have a screening colonoscopy?

Average-risk beneficiaries: every 10 years. High-risk beneficiaries: every 2 years.

6. What qualifies me as high-risk?

High-risk categories include personal history of adenomatous polyps, personal history of colorectal cancer, inflammatory bowel disease (Crohn or ulcerative colitis), family history of colorectal cancer or polyps in a first-degree relative, Lynch syndrome, and familial adenomatous polyposis.

7. How often can I have FIT testing?

Annually for beneficiaries age 45 and older.

8. How often can I have Cologuard testing?

Every 3 years for average-risk asymptomatic beneficiaries age 45 and older.

9. What is the HCPCS code for average-risk screening colonoscopy?

G0121.

10. What is the HCPCS code for high-risk screening colonoscopy?

G0105.

11. Does Medicare cover the cost of a screening colonoscopy?

Yes. ACA Section 4104 waives Part B deductible and coinsurance for USPSTF Grade A or B aligned screening, including colorectal cancer screening modalities, effective January 1, 2011. Beneficiaries pay $0 for the screening service.

12. What if a polyp is removed during my screening colonoscopy?

Under the Consolidated Appropriations Act 2021 Section 122 phased reduction, your coinsurance is reduced. In 2026, you pay 15% coinsurance on the procedure (down from 20%). The reduction continues to 10% in 2027 through 2029 and 0% from 2030 onward.

13. What is the difference between screening and diagnostic colonoscopy?

Screening colonoscopy is performed when you have no symptoms or specific indication beyond screening. Diagnostic colonoscopy is performed because of symptoms (rectal bleeding, abdominal pain, anemia, change in bowel habits) or to evaluate a positive screening test. Diagnostic colonoscopy is subject to standard Part B cost-sharing.

14. Is bowel preparation covered?

Bowel preparation prescription costs may be covered under Part D depending on your prescription drug plan formulary. Over-the-counter polyethylene glycol products are generally not covered.

15. Is anesthesia covered for screening colonoscopy?

Anesthesia services administered by a separate anesthesiologist may be billed separately. The anesthesia service may not be fully waived under the ACA Section 4104 framework, so you may face anesthesia-related coinsurance.

16. Can I have both FIT and colonoscopy?

Generally, beneficiaries choose one screening modality strategy. Concurrent use of FIT plus colonoscopy is not standard and may not be covered as simultaneous screening.

17. What is the Annual Wellness Visit?

The Annual Wellness Visit is a yearly Medicare-covered preventive visit (Section 1861(hhh)) that includes a personalized prevention plan documenting your colorectal cancer screening status and recommendations.

18. What is the Initial Preventive Physical Examination?

The IPPE (Section 1861(ww)) is the one-time "Welcome to Medicare" visit available within the first 12 months of Part B enrollment. It includes assessment of preventive services needs and orders for appropriate screening.

19. Does Medicare Advantage cover colorectal cancer screening?

Yes. Medicare Advantage plans must cover at least the same benefits as Original Medicare, including colorectal cancer screening at the same frequency and with the same cost-sharing protections. Some plans offer enhanced benefits, but provider network constraints may apply.

20. Can I get screened at any gastroenterologist in Georgia?

You can be screened by any gastroenterologist who accepts Medicare assignment under Original Medicare. Under Medicare Advantage, network constraints may apply.

21. What if I have a positive FIT or Cologuard test?

A positive stool-based test indicates the need for follow-up diagnostic colonoscopy. The follow-up colonoscopy is considered diagnostic (not screening) and is subject to standard Part B cost-sharing.

22. How do I find a gastroenterologist in Georgia?

You can search Medicare.gov's care provider directory, contact your primary care physician for a referral, or contact major Georgia gastroenterology programs directly: Emory Digestive Health (404-778-3184), Wellstar Gastroenterology, Piedmont GI, Northside Hospital GI, and Augusta University Digestive Health.

23. Is there a Medicare-covered home colonoscopy alternative?

No. There is no home-administered colonoscopy alternative. The Cologuard FIT-DNA test is the closest home-administered modality with high sensitivity, but it does not replace diagnostic colonoscopy when needed.

24. What happens if I am diagnosed with colorectal cancer?

After a colorectal cancer diagnosis, you transition from screening to active treatment and surveillance. Treatment costs are covered under standard Medicare benefits (surgery, chemotherapy, radiation as indicated). After treatment, you transition to surveillance protocols rather than screening protocols.

25. Does Medicare cover hereditary cancer genetic testing?

Medicare covers genetic testing in specific clinical contexts when medical necessity is documented. Coverage is determined by Local Coverage Determinations through the Medicare Administrative Contractor (Palmetto GBA for Georgia) and case-specific medical necessity review.

26. Where can I get help understanding my colorectal cancer screening coverage in Georgia?

Contact GeorgiaCares SHIP (1-866-552-4464) for free, unbiased Medicare counseling. You can also contact Medicare directly at 1-800-MEDICARE, the Medicare Rights Center at 1-800-333-4114, the American Cancer Society at 1-800-227-2345, or the Colorectal Cancer Alliance at 1-877-422-2030.

Contacts and Resources

1. Medicare — 1-800-MEDICARE (1-800-633-4227) for general Medicare questions and coverage.
2. Palmetto GBA Medicare Administrative Contractor — 1-866-238-9650 for Medicare claims and coverage in Georgia.
3. Georgia Department of Community Health Member Services — 1-866-211-0950 for Georgia Medicaid coordination.
4. GeorgiaCares SHIP — 1-866-552-4464 for free Medicare counseling.
5. Medicare Rights Center — 1-800-333-4114 for Medicare advocacy and assistance.
6. Atlanta Legal Aid — 404-377-0701 for legal assistance with Medicare issues.
7. Georgia Legal Services Program — 1-800-498-9469 for legal assistance outside metropolitan Atlanta.
8. 211 Georgia — Dial 211 for community resource referrals.
9. Eldercare Locator — 1-800-677-1116 for connection to local aging services.
10. Georgia Department of Public Health — 404-657-2700 for state public health resources.
11. American Cancer Society — 1-800-227-2345 for cancer information, support, and resources.
12. Colorectal Cancer Alliance — 1-877-422-2030 for colorectal cancer-specific information and patient support.
13. American College of Gastroenterology — 301-263-9000 for professional gastroenterology information.
14. American Gastroenterological Association — 301-654-2055 for additional gastroenterology professional resources.
15. Emory Digestive Health — 404-778-3184 for academic gastroenterology in Atlanta.
16. Wellstar Gastroenterology — Network gastroenterology in north and west Georgia.
17. Piedmont GI — Piedmont Healthcare gastroenterology services across Georgia.
18. Acentra Health QIO — 1-844-455-8708 for Medicare quality of care concerns.